

> 


# LUNG CANCER

![](https://i.imgur.com/CkTApOO.jpg)

(_NEJM_ 2008;359:1367; _JCO_ 2012;30:863; _J Thorac Oncol_ 2012;7:924; _Nature_ 2011;489:519; _Cell_ 2012;150:1107)

流行病學 and risk factors

• Most common cause of cancer-related death for both men and women in the U.S.

• **Cigarette smoking:** 85% of lung cancers occur in smokers; risk ∝ total pack-yrs, ↓ risk after quitting/reducing but not to baseline (_Int J Cancer_ 2012;131:1210)

squamous & small cell almost exclusively in smokers

adenocarcinoma most common type in nonsmokers

• Asbestos: when combined with smoking, synergistic ↑ in risk of lung cancer

• Other: RT (for other cancer); HIV; environ. toxins (radon, 2nd\-hand smoke); pulm. fibrosis

臨床表現

• ~10% asymptomatic at dx, detected incidentally (only 16% with localized dis. at presentation)

• **Endobronchial growth** of 1° tumor: **cough**, **hemoptysis**, **dyspnea**, pain, wheezing, post-obstructive pneumonia; more common with squamous or small cell (central location)

• **Regional spread**

### Pleural effusion, pericardial effusion, hoarseness (recurrent laryngeal nerve palsy), dysphagia (esophageal compression), stridor (tracheal obstruction)

**Pancoast’s syndrome:** apical tumor → brachial plexus involvement (C8, T1, T2) → Horner’s syndrome, shoulder pain, rib destruction, atrophy of hand muscles

### SVC syndrome (_NEJM_ 2007;356:1862): central tumor → SVC compression → face/arm swelling (>80%), neck/chest vein distention (~60%), SOB/cough (~50%), HA (~10%); Rx = steroids, diuretics, RT ± chemo, SVC stent if severe 症狀, anticoag if clot

• **Extrathoracic metastases:** brain, bone, liver, adrenal, weight loss

• **Paraneoplastic syndromes**

_Endocrine:_

ACTH (SCLC) → **Cushing’s syndrome;** ADH (SCLC) → **SIADH**

PTH-rP (squamous cell) → **hypercalcemia**

_Skeletal:_ digital clubbing (non-small cell), **hypertrophic pulm. osteoarthropathy** (adenocarcinoma) = symmetric polyarthritis and proliferative periostitis of long bones

_Neurologic_ (SCLC): **Eaton-Lambert** (anti-P/Q-type voltage-gated Ca2+ channel Abs), peripheral neuropathy (anti-Hu, anti-PCA-2, anti-CRMP5), cerebellar degeneration (anti-Hu, anti-Yo, anti-Ri, anti-Tr), encephalomyelitis (anti-Hu, anti-Ma1/2, anti-CRMP5)

_Cutaneous:_ acanthosis nigricans, dermatomyositis

_Hematologic:_ hypercoagulable state (adenocarcinoma), DIC, marantic endocarditis

Screening (_Lancet_ 2014;382:732)

• No benefit to CXR or sputum cytology, even in high-risk 病人

• **Annual low-dose chest CT** in ≥30 pack-y current or former (quit within 15 y) smokers, age 55–74 y → 20% ↓ lung cancer-related mortality (_NEJM_ 2011;365:395; 2013;368:1980; USPSTF)

number needed to screen = 320; high false ⊕ rate

consider risk scores to target screening (_NEJM_ 2013;369:245 & 910; _JAMA_ 2016;315:2300)

Diagnostic and staging evaluation (_NCCN Guidelines_ v.1.2019)

• **Initial imaging:** contrast chest CT including liver and adrenals

• **Pathology:** via **bronchoscopy** (central lesions) or **CT-guided needle bx** (peripheral lesions or accessible sites of suspected metastasis); mediastinoscopy (LN bx), VATS (eval. of pleura peripheral lesions), thoracentesis (cell block for cytology)

• **TNM staging:** based on tumor size and extent of invasion (T), regional LN involvement \[N: N0 (none), N1 (ipsilat. hilar), N2 (ipsilat. mediast.), N3 (contralat., supraclav.)\] and presence of metastases (M) (_Chest 2017_;151:193). 5-y survival: ~70-90% for stage I, 50-60% stage II, 15–35% stage III, 0–10% stage IV (_J Thorac Oncol_ 2016;11:39).

• **Pre治療 evaluation**

_Intrathoracic:_ **mediastinoscopy** (± preceded by U/S-guided transesoph. or transbronch. needle aspiration; _JAMA_ 2010;304:2245) or **VATS;** thoracentesis if pleural effusion

_Extrathoracic:_ **PET-CT** more Se than CT alone for detecting mediastinal and distant mets as well as bone mets (_NEJM_ 2009;361:32); **brain MRI** for all 病人 (except stage IA)

• **Genetics:** ✔ _EGFR_ mut., _ALK, ROS1, RET, BRAF, NTRK_ fusion for adv/metastatic non-squamous dis. (note incidence lower in squamous; only test if nonsmoker, mixed histo)

• 肺功能 with quantitative V/Q if planned 治療 includes surgical resection; need to have 30% of normal, predicted lung fxn _after_ resection

NSCLC 治療 (_Lancet_ 2017;389:299; _NEJM_ 2017;377:849; _NCCN Guidelines_ v.1.2019)

### Figure 5-6 NSCLC 治療 algorithm

![](https://i.imgur.com/wuuUNyF.jpg)

_NEJM_ 2018;379:2342. Encouraging data on PD-1 blockade as _neoadjuvant_ therapy (_NEJM_ 2018;378:1976).

![](https://i.imgur.com/jWcBFyl.jpg)

TKI toxicities: rash & diarrhea (common); lung & liver injury (rare but potentially serious)

SCLC staging and 治療 (NCCN Guidelines v.1.2019)

• SCLC usually disseminated at presentation but can be very responsive to chemoradiation

• **Chemotherapy** (platinum + etoposide) is primary 治療 modality

• Addition of anti-PD-L1 Ab (eg, atezolizumab) ↑ survival (_NEJM_ 2018;379:2220)

• **Thoracic radiation** added to chemotherapy improves survival in limited-stage disease

• **Prophylactic cranial irradiation** (PCI) ↑ survival for limited disease in complete remission (_NEJM_ 1999;341:476) & ↓ symptomatic brain mets in extensive disease (_NEJM_ 2007;357:664)

![](https://i.imgur.com/LIM0kdY.jpg)
